179 related articles for article (PubMed ID: 35882692)
1. Peritoneal Metastases of Colorectal Origin Treated with Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy: The Efficiency of Mitomycin C.
Delhorme JB; Sauvinet G; Séverac F; Diab S; Liu D; Rohr S; Romain B; Brigand C
Ann Surg Oncol; 2022 Nov; 29(12):7568-7576. PubMed ID: 35882692
[TBL] [Abstract][Full Text] [Related]
2. Safety of intraperitoneal Mitomycin C versus intraperitoneal oxaliplatin in patients with peritoneal carcinomatosis of colorectal cancer undergoing cytoreductive surgery and HIPEC.
van Eden WJ; Kok NFM; Woensdregt K; Huitema ADR; Boot H; Aalbers AGJ
Eur J Surg Oncol; 2018 Feb; 44(2):220-227. PubMed ID: 29258720
[TBL] [Abstract][Full Text] [Related]
3. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery.
Prada-Villaverde A; Esquivel J; Lowy AM; Markman M; Chua T; Pelz J; Baratti D; Baumgartner JM; Berri R; Bretcha-Boix P; Deraco M; Flores-Ayala G; Glehen O; Gomez-Portilla A; González-Moreno S; Goodman M; Halkia E; Kusamura S; Moller M; Passot G; Pocard M; Salti G; Sardi A; Senthil M; Spiliotis J; Torres-Melero J; Turaga K; Trout R
J Surg Oncol; 2014 Dec; 110(7):779-85. PubMed ID: 25088304
[TBL] [Abstract][Full Text] [Related]
4. Optimal perfusion chemotherapy: A prospective comparison of mitomycin C and oxaliplatin for hyperthermic intraperitoneal chemotherapy in metastatic colon cancer.
Woeste MR; Philips P; Egger ME; Scoggins CR; McMasters KM; Martin RCG
J Surg Oncol; 2020 Jun; 121(8):1298-1305. PubMed ID: 32239529
[TBL] [Abstract][Full Text] [Related]
5. Oxaliplatin versus Mitomycin C following complete cytoreduction for colorectal peritoneal metastases: a comparative study.
Narasimhan V; Warrier S; Michael M; Ramsay R; Heriot A
J Gastrointest Surg; 2020 Sep; 24(9):2104-2112. PubMed ID: 31745907
[TBL] [Abstract][Full Text] [Related]
6. Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS).
Baratti D; Kusamura S; Azmi N; Guaglio M; Montenovo M; Deraco M
Ann Surg Oncol; 2020 Jan; 27(1):98-106. PubMed ID: 31691116
[TBL] [Abstract][Full Text] [Related]
7. Mitomycin-C versus oxaliplatin during cytoreductive surgery and HIPEC for peritoneal metastases secondary to colorectal carcinoma: a retrospective analysis.
Spiliotis J; Kalles V; Prodromidou A; Raptis A; Ferfelis M; Christopoulou A; Tsiatas M
J BUON; 2021; 26(4):1260-1265. PubMed ID: 34564979
[TBL] [Abstract][Full Text] [Related]
8. Systematic review of published literature on oxaliplatin and mitomycin C as chemotherapeutic agents for hyperthermic intraperitoneal chemotherapy in patients with peritoneal metastases from colorectal cancer.
Wisselink DD; Braakhuis LLF; Gallo G; van Grevenstein WMU; van Dieren S; Kok NFM; de Reuver PR; Tanis PJ; de Hingh IHJT
Crit Rev Oncol Hematol; 2019 Oct; 142():119-129. PubMed ID: 31400583
[TBL] [Abstract][Full Text] [Related]
9. Oxaliplatin versus Mitomycin C for HIPEC in colorectal cancer peritoneal carcinomatosis.
Leung V; Huo YR; Liauw W; Morris DL
Eur J Surg Oncol; 2017 Jan; 43(1):144-149. PubMed ID: 27780675
[TBL] [Abstract][Full Text] [Related]
10. Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: A nationwide comparative study.
Bakkers C; van Erning FN; Rovers KP; Nienhuijs SW; Burger JW; Lemmens VE; Aalbers AG; Kok NF; Boerma D; Brandt AR; Hemmer PH; van Grevenstein WM; de Reuver PR; Tanis PJ; Tuynman JB; de Hingh IH
Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1902-1907. PubMed ID: 32340819
[TBL] [Abstract][Full Text] [Related]
11. Oxaliplatin versus mitomycin C in HIPEC for peritoneal metastasis from colorectal cancer: a systematic review and meta-analysis of comparative studies.
Zhang X; Wu Q; Wei M; Deng X; Gu C; Wang Z
Int J Colorectal Dis; 2020 Oct; 35(10):1831-1839. PubMed ID: 32725345
[TBL] [Abstract][Full Text] [Related]
12. 2022 Peritoneal Surface Oncology Group International Consensus on HIPEC Regimens for Peritoneal Malignancies: Colorectal Cancer.
Hübner M; van Der Speeten K; Govaerts K; de Hingh I; Villeneuve L; Kusamura S; Glehen O
Ann Surg Oncol; 2024 Jan; 31(1):567-576. PubMed ID: 37940803
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Survival in Patients with Isolated Peritoneal Carcinomatosis from Colorectal Cancer Treated with Cytoreduction and Melphalan or Mitomycin-C as Hyperthermic Intraperitoneal Chemotherapy Agent.
Sipok A; Sardi A; Nieroda C; King MC; Sittig M; Gushchin V
Int J Surg Oncol; 2018; 2018():1920276. PubMed ID: 30643644
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory bowel disease drastically affects the prognosis of patients treated for peritoneal metastases with combined cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A multicenter study.
Hammoudi N; Eveno C; Lambert J; Maillet M; Glehen O; Goere D; Lourenco N; Allez M; Aparicio T; Pocard M; Gornet JM;
Eur J Surg Oncol; 2018 Jun; 44(6):799-804. PubMed ID: 29650418
[TBL] [Abstract][Full Text] [Related]
15. Morbidity associated with the use of oxaliplatin versus mitomycin C in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal or appendiceal origin: a multi-institutional comparative study.
Benzaquen E; Wang Y; Wiseman S; Rosenfeld V; Sideris L; Dubé P; Pelletier JS; Vanounou T
Can J Surg; 2021 Mar; 64(2):E111-E118. PubMed ID: 33651573
[TBL] [Abstract][Full Text] [Related]
16. GECOP-MMC: phase IV randomized clinical trial to evaluate the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) with mytomicin-C after complete surgical cytoreduction in patients with colon cancer peritoneal metastases.
Pereira F; Serrano A; Manzanedo I; Pérez-Viejo E; González-Moreno S; González-Bayón L; Arjona-Sánchez A; Torres J; Ramos I; Barrios ME; Cascales P; Morales R; Boldó E; García-Fadrique A; Arteaga X; Gutierrez-Calvo A; Sánchez-García S; Asensio E; Ramírez CP; Artiles M; Vaqué J; Parra PA; Villarejo P; Muñoz-Casares C; Turienzo E; Calero A; Torrejimeno IJ; Prieto I; Galindo J; Borrego V; Marcello ME; Rihuete C; Carrasco J; Gomez-Quiles L
BMC Cancer; 2022 May; 22(1):536. PubMed ID: 35549912
[TBL] [Abstract][Full Text] [Related]
17. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal and appendiceal peritoneal metastases - The Hong Kong experience and literature review.
Chow FC; Yip J; Foo DC; Wei R; Choi HK; Ng KK; Lo OS
Asian J Surg; 2021 Jan; 44(1):221-228. PubMed ID: 32605790
[TBL] [Abstract][Full Text] [Related]
18. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial.
Quénet F; Elias D; Roca L; Goéré D; Ghouti L; Pocard M; Facy O; Arvieux C; Lorimier G; Pezet D; Marchal F; Loi V; Meeus P; Juzyna B; de Forges H; Paineau J; Glehen O;
Lancet Oncol; 2021 Feb; 22(2):256-266. PubMed ID: 33476595
[TBL] [Abstract][Full Text] [Related]
19. Hyperthermic Intraperitoneal Chemotherapy with Mitomycin C versus Oxaliplatin after Cytoreductive Surgery for the Treatment of Peritoneal Metastases of Colorectal Cancer Origin.
Papageorgopoulou C; Nikolakopoulos K; Seretis C
Chirurgia (Bucur); 2022 Jun; 117(3):266-277. PubMed ID: 35792537
[No Abstract] [Full Text] [Related]
20. Organoids from colorectal peritoneal metastases as a platform for improving hyperthermic intraperitoneal chemotherapy.
Ubink I; Bolhaqueiro ACF; Elias SG; Raats DAE; Constantinides A; Peters NA; Wassenaar ECE; de Hingh IHJT; Rovers KP; van Grevenstein WMU; Laclé MM; Kops GJPL; Borel Rinkes IHM; Kranenburg O
Br J Surg; 2019 Sep; 106(10):1404-1414. PubMed ID: 31197820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]